Tivantinib is an inhibitor of MET and GSK-3α/β that exhibits anticancer chemotherapeutic activity. Tivantinib inhibits proliferation of non-small cell lung cancer (NSCLC) cells and is currently undergoing clinical trials, showing improvements in time to progression and overall survival in the treatment of hepatocellular carcinoma.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.